BIM
PTX

BlackRock Investment Management’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

BlackRock Investment Management’s Portfolio PTX Stock Details PTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-16,088
Closed -$169K – 4207
2016
Q1 		$169K Buy
16,088
+394
+3% +$7.83K ﹤0.01% 3191
2015
Q4 		$463K Buy
15,694
+40
+0.3% +$1.21K ﹤0.01% 3030
2015
Q3 		$495K Sell
15,654
-353
-2% -$16.9K ﹤0.01% 3030
2015
Q2 		$948K Buy
16,007
+6,361
+66% +$449K ﹤0.01% 2806
2015
Q1 		$1.03M Buy
9,646
+31
+0.3% +$2.95K ﹤0.01% 2503
2014
Q4 		$903K Sell
9,615
-118
-1% -$11.3K ﹤0.01% 2613
2014
Q3 		$747K Buy
9,733
+139
+1% +$10.9K ﹤0.01% 2712
2014
Q2 		$862K Buy
9,594
+3,644
+61% +$223K ﹤0.01% 2709
2014
Q1 		$318K Buy
5,950
+101
+2% +$3.33K ﹤0.01% 3146
2013
Q4 		$147K Sell
5,849
-33
-0.6% -$786 ﹤0.01% 3247
2013
Q3 		$160K Buy
5,882
+325
+6% +$10.5K ﹤0.01% 3209
2013
Q2 		$201K Buy
+5,557
New +$208K ﹤0.01% 3163

Other funds holding PTX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

BlackRock Investment Management's PTX Position: Q2 2016 in Review

BlackRock Investment Management sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q2 2016, closing a stake of 16,088 shares — an estimated $169K sold.

BlackRock Investment Management first reported a position in PTX in Q2 2013 and held it in 12 quarters. The position peaked at $1.03M in Q1 2015. 56 funds tracked by Wall St. Rank hold PTX as of Q2 2016.

  • BlackRock Investment Management reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q2 2016 after selling out during the quarter.
  • BlackRock Investment Management sold 16,088 Pernix Therapeutics Holdings, Inc. shares in Q2 2016, an estimated $169K.
  • BlackRock Investment Management first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and held it in 12 quarters.
  • BlackRock Investment Management's Pernix Therapeutics Holdings, Inc. position peaked at $1.03M in Q1 2015.
  • 56 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q2 2016.

Based on BlackRock Investment Management's 13F filing for Q2 2016, filed 10 Aug 2016.